

# HSJ Diabetes Mellitus Network – North West

The regional HSJ Regional Network meetings are initiated and organised by Wilmington Healthcare. This event is supported by Ascensia, Hicom, MSD, Novo Nordisk and Takeda through the provision of sponsorship. These companies have had no input into the design or content of the agenda but will be present on the day.

**Date:** Wednesday 28 November

**Venue:** Holiday Inn Haydock, WA12 0JG

**Chair:** Professor Ian Macdonald - Professor of Metabolic Physiology, University of Nottingham; NHS Ethics Committee Researcher; Joint Editor of the International Journal of Obesity; International Union of Nutritional Sciences Fellow; Royal Society of Biology Fellow; Association for Nutrition Fellow; UK Scientific Advisory Committee on Nutrition Member

<b>12.15pm</b>	Registration and buffet lunch	<b>2.55pm</b>	NICE Update: Diabetes prevention, detection and treatment: <b>Rachel Reid - Implementation Facilitator, NICE Field Team (North)</b>
<b>1pm</b>	Aims and Objectives: <b>Paul Midgley - Director of NHS Insight and HSJ Regional Networks, Wilmington Healthcare</b>		
<b>1.05pm</b>	Chair Introduction: <b>Prof Ian Macdonald</b>		
<b>1.15pm</b>	Regional update: <b>Clare Howarth - Head of the North, Diabetes UK</b>		
	<b>Session One: Transforming Prevention of T2D</b>		<b>Session Two: Transforming Management of T2D</b>
<b>1.35pm</b>	NDPP roll out in an STP world: <b>Katie Mills - NDPP Implementation Lead for Cheshire &amp; Merseyside HCP</b>	<b>3.10pm</b>	Remission from T2D – what's possible: <b>Prof Ian Macdonald</b>
<b>1.50pm</b>	Facilitated table discussion: <ul style="list-style-type: none"> <li>• How has the uptake of DPP changed in your area in the last 6 months for patients at highest risk of developing T2D?</li> <li>• What have you done in the last 6 months to improve access for those in this high risk group for whom the DPP format/time commitment isn't suitable?</li> <li>• How are the positive health behaviour changes made after an individual has completed the initial DPP programme being sustained thereafter?</li> <li>• Who else beyond primary care needs to be able to refer into DPP and how do we engage them as part of the wider STP/ICS diabetes plan?</li> </ul>	<b>3.20pm</b>	Peripheral Artery Disease – why we need a community clinic rather than overload our secondary care: <b>Dr Anita Sharma - NICE QSAC GP Member</b>
		<b>3.35pm</b>	Facilitated table discussion <ul style="list-style-type: none"> <li>• What is your experience of initiating diabetes reversal/remission therapy?</li> <li>• In your local area, do you have recently updated clinical guidelines for managing T2D? How well monitored are they for adherence? Could this be improved, if so how? What would the benefits be for patients and the local NHS?</li> <li>• What ideas or innovations could you adopt/adapt to improve patient outcomes and reduce the cost of T2D?</li> </ul>
<b>2.10pm</b>	Feedback/Panel Q&A: speakers	<b>4.05pm</b>	Feedback/Panel Q&A, speakers
<b>2.40pm</b>	Break	<b>4.25pm</b>	Summary and key learning points: <b>Prof Ian Macdonald</b>
		<b>4.30pm</b>	Close

Wilmington Healthcare Limited reserves the right to change timings, content and speakers at any time

## **HSJ Diabetes Mellitus Network – North West**

The regional HSJ Regional Network meetings are initiated and organised by Wilmington Healthcare. These Events are supported by Napp and Hicom through the provision of sponsorship. MSD and Takeda have also paid to attend. These companies have had no input into the design or content of the agenda but will be present on the day.

### **Presentation Overviews**

#### **Chair Introduction**

Professor Ian Macdonald will give an introduction to the research evidence behind obesity, diet and movement and the link to type 2 diabetes, and ongoing work in this area and how this may predict future policy around diabetes prevention strategies.

#### **NDPP Roll Out in an STP World**

Cheshire & Merseyside is a Wave 3 site which went live in July 2018. This presentation covers the governance structure of the programme as well an overview of the implementation plan. Bringing together 7 wave 1 CCG's, on 4 contracts with two different providers and 4 new wave 3 CCG's all onto a new wave 3 contract with a new provider. Implementation plans had to also include the management of the transition from the old providers to the new providers with hundreds of patients data being transferred. The presentation will look at the challenges that have been overcome as well as celebrate the successes so far.

#### **NICE Update: Diabetes prevention, detection and treatment**

This presentation will provide an overview of NICE; in particular this session focuses on what NICE has done to support diabetes prevention, detection and treatment. It also runs through NICE quality standards for diabetes and details how to use them to support quality improvement, as well as provide an overview of the tools and resources NICE has produced to support the implantation of guidelines and quality standards.

#### **Update on reversing T2D**

Professor Ian Macdonald will give an introduction to the research evidence behind reversal of type 2 diabetes, and ongoing work in this area and how this may impact on optimal scenarios around type 2 diabetes management.